Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites

Cancer Cytopathology

Volumn 122, Issue 7, 2014, Pages 504-511

  Beca, Francisco ^a,b,c   Schmitt, Fernando ^b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fine needle aspiration (FNA); Metastases; Tumoral heterogeneity

Indexed keywords

FINE-NEEDLE ASPIRATION (FNA); METASTASES; TUMORAL HETEROGENEITY;

BIOPSY, NEEDLE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84904278509     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21395     Document Type: Review

References (56)

1. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Na Rev Cancer. 2003;3:453-458.
2. Lorusso G, Ruegg C. New insights into the mechanisms of organspecific breast cancer metastasis. Semin Cancer Biol. 2012;22: 226-233.
3. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-28.
4. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283:139-146.
5. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Eng J Med. 2013;368:842-851.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.
7. Weinberg RA. The Biology of Cancer. New York: Garland Science; 2007.
8. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90-94.
9. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest. 2011;121:3810-3818.
10. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-117.
11. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999-1005.
12. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277-302.
13. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302-312.
14. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med. 1956;76: 988-1000.
15. Steel GG, Lamerton LF. The growth rate of human tumours. Br J Cancer. 1966;20:74-86.
16. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284-297.
17. Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22:818-827.
18. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clini Cancer Res. 2010;16:790-799.
19. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47.
20. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
21. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:4680-473.
22. Ciriello G, Miller ML, Aksoy BA, et al. Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013; 45:1127-1133.
23. Niikura N, Odisio BC, Tokuda Y, et al. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013;10:711-719.
24. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587-592.
25. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499-1504.
26. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-990.
27. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2:20ra14.
28. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra168.
29. Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol. 2008;61:258-267.
30. Schmitt FC, Vielh P. Molecular biology and cytopathology. Principles and applications. Ann Pathol. 2012;32:e57-63, 444-450.
31. Schmitt F, Barroca H. Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol. 2012;120:145-160.
32. Di Lorito A, Schmitt FC. (Cyto)pathology and sequencing: Next (or last) generation? Diagn Cytopathol. 2012;40:459-461.
33. Annaratone L, Marchio C, Renzulli T, et al. High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer. Transl Oncol. 2012;5: 180-189.
34. Costa J, Gerhard R, Rossi E, et al.Massive Parallel Sequencing To Assess the Mutational Landscape of Fine Needle Aspirate Samples: A Pilot Study. Paper presented at: Lab Invest 2013.
35. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
36. Wilking U, Karlsson E, Skoog L, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125:553-561.
37. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225-5232.
38. Andre T, Blons H, Mabro M, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: A GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24: 412-419.
39. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
40. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26:158-163.
41. Pang NK, Nga ME, Chin SY, et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology. 2011;22: 358-364.
42. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: A paradigm shift. J Thorac Oncol. 2010;5:411-414.
43. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
44. Ulivi P, Romagnoli M, Chiadini E, et al. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol. 2012;41:147-152.
45. Khode R, Larsen DA, Culbreath BC, et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol. 2013;121: 361-369.
46. Cai G, Wong R, Chhieng D, et al. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013;121:500-507.
47. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60-e69.
48. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
49. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell. 2004;116:855-867.
50. Hookim K, Roh MH, Willman J, et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathol. 2012;120:52-61.
51. Bernacki KD, Betz BL, Weigelin HC, et al. Molecular diagnostics of melanoma fine-needle aspirates: A cytology-histology correlation study. Am J Clin Pathol. 2012;138:670-677.
52. Zimmermann AK, Camenisch U, Rechsteiner MP, Bode- Lesniewska B, Rossle M. Value of immunohistochemistry in the detection of BRAF mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 2014;122:48-58.
53. Rivenbark AG, O'Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183:1113-1124.
54. McCourt CM, McArt DG, Mills K, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013;8:e69604.
55. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039-1049.
56. Young G, Wang K, He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013;121:688-94.